A gene editing therapy developed by Verve has shown promising results in an early study, lowering cholesterol levels. The therapy appears to be as effective as existing treatments, such as PCSK9 inhibitors, in reducing cholesterol. The study's outcome may have implications for the treatment and potential prevention of heart disease, with some suggesting it could be a significant development for people with high cholesterol.